Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05180279
Other study ID # 19051402
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date June 1, 2024

Study information

Verified date June 2024
Source Rush University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate if circadian malalignment (unusual sleeping patterns), such as night shifts (sleeping during the day and being awake during the night time), worsens the inflammation of the gut. We hope to look at patients with Ulcerative Colitis and Healthy Controls.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date June 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: UC patients: - M/F, 18-50 y/o - Inactive Disease (Mayo Score = 2) - Stable medications with no disease flares for the > 3 months - Left-sided UC (Montreal E1 or E2) - Normal psychological evaluation and negative drug screen (See Below) Healthy Controls: - M/F, 18-50 y/o, age ± 3y sex, race, and BMI match with UC subject - No clinical evidence of any medical illness - Normal psychological evaluation and negative drug screen (See Below) Exclusion Criteria: UC patients: - Patients with other forms of colitis such as Crohn's disease (CD) or indeterminate colitis - Patient with active UC (Mayo > 2) - Pancolonic UC (colitis past the splenic flexure, Montreal E3)) - Use of biologic or immunomodulatory medications (i.e. Infliximab, Adalimumab, azathioprine, Vedolizumab, methotrexate, etc.) - Gastrointestinal surgery - Other GI diseases or systemic diseases (cardiac, renal failure, cirrhosis) - Shift work in the last 6 months - Antibiotic use within last 12 weeks - Patients who have used anti-diarrheal agents such as Lomotil or Imodium within 3 days of the study - Prednisone use the last 30 days - Significant Depression (score = 14 BDI) - Significant Anxiety (score = 40 STAI) - Use of probiotic supplement in last 4 weeks except yogurt. - Intentional change in diet. - Chronic use of NSAIDS. A washout period of 3 weeks is needed before the subject could be enrolled into the study. Low dose aspirin is allowed. - Chronic Alcohol use. A washout period of 3 weeks is needed before the subject could be enrolled into the study. - Have children under 6 months Healthy Controls: - History of drug abuse, gastrointestinal (GI) surgery, GI diseases, or systemic diseases such as renal (creatinine>1.2 mg/dl), liver, cardiac, or diabetes (Hgb-A1c>8%) - Antibiotic use within last 12 weeks - Shift work in the last 6 months - Use of probiotic supplement except yogurt in last 4 weeks. - Atypical American diet with daily fiber = 16 grams or daily saturated fat = 11 grams by Food Frequency Questionnaire - Chronic use of NSAIDS. A washout period of 3 weeks is needed before the subject could be enrolled into the study. - Chronic Alcohol use. A washout period of 3 weeks is needed before the subject could be enrolled into the study. - Significant Depression (score = 14 BDI) - Significant Anxiety (score = 40 STAI) - Regular use of medications that affect intestinal permeability, intestinal motility and/or endogenous melatonin including metoclopramide, NSAIDs, antibiotics, beta blocker, psychotropic medication, hypnotics and exogenous melatonin products during 4 weeks prior to the study - People who crossed more than 2 time zones in the previous month - Inability to sign an informed consent form. - Have children under 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
7-day sleep lab
Patients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored. They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection. Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.

Locations

Country Name City State
United States Rush University Medical Center Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Rush University Medical Center National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Diet Vioscreen Food Frequency Questionnaire (FFQ). Total of 19 measured food components. Vioscreen captures comprehensive dietary behaviors in just 30 minutes. It is a unique dietary questionnaire, management and analysis system that efficiently gathers and manages data that immediately identifies dietary "habits" and counsel for lifestyle changes. Once before sleep lab
Other Single day food recall Automated Self-Administered 24-Hour Recall (ASA24) Dietary Assessment. Total nutrients from all supplements reported in a given day. Once before sleep lab
Other Chronotype The Munich ChronoType Questionnaire (MCTQ) uses a self-rated scale to assess individual phase of entrainment on work and work-free days; it is a tool to collect primary sleep times, such as bed- and rise-times, plus the clock time of becoming fully awake as well as sleep latency and inertia, in addition to other time points. Screening
Other Inflammatory Bowel Disease Questionnaire 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32) is the most frequently used instrument to capture disease-specific quality of life in randomized clinical trials for ulcerative colitis Screening
Other Beck Depression Inventory The Beck Depression Inventory (BDI, BDI-II), created by Dr. Aaron T. Beck, is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. 3 Weeks prior to circadian lab assessments
Other The State-Trait Anxiety Inventory The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety Screening
Other Perceived Stress Questionnaire Consisting of 30 items, the Perceived Stress Questionnaire was developed as an instrument for assessing the stressful life events and circumstances that tend to trigger or exacerbate disease symptoms. Screening
Other The International Restless Legs Syndrome Study Group Rating Scale Subjective scale to measure disease severity of restless legs syndrome in the past week Screening
Other Berlin Questionnaire The questionnaire consists of 3 categories related to the risk of having sleep apnea Screening
Other Pittsburgh Sleep Quality Index The following questions relate to your usual sleep habits during the past month only. 3 Weeks prior to circadian lab assessments
Primary Change in the Phase Angle of Entrainment from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment Phase angle of entrainment is the amount of time between dim light melatonin onset to sleep onset. Melatonin concentration in blood serum is measured by ELISA (enzyme-linked immunosorbent assay). Blood drawn hourly for eight hours at baseline circadian rhythm (eight draws) and blood drawn hourly for twelve hours at circadian misalignment (12 draws).
Primary Change in Intestinal Permeability from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment Intestinal permeability is assessed through spectrophotometric measurements of sucralose, sucrose, maltose and lactulose concentrations in urine following ingestion of a sugar cocktail. 24 hour urine collection beginning at baseline and 24 hour urine collection at circadian misalignment.
Secondary Change in 24 hour Urinary Melatonin Concentrations from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment Spectrophotometry 24 hour urine collection at baseline and 24 hour urine collection at circadian misalignment circadian
Secondary Change in Mayo Score from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment Within the endoscopic component of the Mayo Score, a score of 0 is given for normal mucosa or inactive UC, while a score of 1 is given for mild disease with evidence of mild friability, reduced vascular pattern, and mucosal erythema. 30 minute flexible sigmoidoscopy at Baseline and 30 minute flexible sigmoidoscopy at Circadian Misalignment
Secondary Change in Stool Calprotectin from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment Calprotectin is a sensitive marker for inflammation in the gastrointestinal tract. Measured through enzyme linked immunosorbent assay for calprotectin in stool extract. 10 minute stool collection conducted at baseline circadian rhythm and at circadian misalignment.
Secondary Change in Concentration of Serum Cytokine Markers of Inflammation from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment Enzyme linked immunosorbent assay Blood is drawn every two hours over a 24 hour period at baseline (12 draws), and blood is drawn every two hours over a 24 hour period at circadian misalignment
Secondary Changes in Clock Gene Expression in Peripheral Blood Mononuclear Cells from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment RNA Sequencing Blood is drawn every two hours over a 24 hour period at baseline (12 draws), and blood is drawn every two hours over a 24 hour period at circadian misalignment
Secondary Changes in Gene Expression of Colonic Tissue Biopsies from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment Tissue biopsies collected during flexible sigmoidoscopy conducted at Baseline Circadian Rhythm and at Circadian Misalignment. Assessed through histology and RNA Sequencing 30 minute flexible sigmoidoscopy at Baseline and 30 minute flexible sigmoidoscopy at Circadian Misalignment
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2